Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 4, 2026, 00:43Join the 2026 Rising Stars Webinar On February 11 – SSR
-
Feb 4, 2026, 00:18Dalia Alqarni: Urinary Incontinence’s Impact on Women’s Health
-
Feb 4, 2026, 00:16New Study Reveals IVF Success for Women With Endometriosis – Fertility Plus
-
Feb 4, 2026, 00:13Tamuka Chekero: Exploring Relational Autonomy in Infertility Across Cultures
-
Feb 2, 2026, 13:04Optimal GnRH Agonist Dosage for Oocyte Maturation – Fertility and Sterility
-
Feb 2, 2026, 12:39Family Planning Challenges for Women with Lupus – The Lupus Foundation of Australasia
-
Feb 2, 2026, 12:17Anis Feki: Innovative Strategies for Bowel Endometriosis Management
-
Feb 2, 2026, 12:10Revolutionizing Testicular Cell Cultivation with 3D Bioprinting – School of Infection, Inflammation and Immunology, University of Birmingham
-
Feb 2, 2026, 12:07Cesar Diaz Garcia: Age and Its Impact on Male Fertility